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Introduction
Significant advances in the management of 
haemophilia have been achieved in the past several 
decades. These include the development of safe and 
efficacious plasma-derived and recombinant clotting 
factor products, use of prophylaxis as standard of 
care in bleeding prevention and appropriate surgical 
management of haemophilic arthropathy. Despite these 
advances, the development of high-titre anti-factor 
antibodies (inhibitors) remains an unresolved challenge 
in the management of people with haemophilia.
Inhibitors develop in 25-30% of patients with 
severe haemophilia A and in 1-5% of those with severe 
haemophilia B1-3. They were first described by Lawrence 
and Johnson in 19414, and in the seven decades that 
followed our knowledge of their pathophysiology and 
risk factors remains incomplete and continues to evolve. 
This is partly a result of the small inhibitor population 
with significant intra- and inter-individual variability 
making the conduct of studies and interpretation of 
results difficult. The main reason for our incomplete 
knowledge in this area is that inhibitor development 
is a multi-factorial event resulting from the variable 
interplay between several genetic (non-modifiable) 
and non-genetic (modifiable to some extent) risk 
factors. Despite these limitations, a number of clinical 
evaluations analysing treatment of inhibitor patients 
have been performed including randomised controlled 
prospective studies5,6. These studies provide, in part, the 
evidence basis for our current inhibitor management 
principles and practice. 
Inhibitors remain a popular subject of haemostasis 
scientific meetings and many issues related to their 
pathophysiology and management are discussed and 
debated in the published literature. The main issues 
include: (i) the identification of clinically relevant risk 
factors for inhibitor development, (ii) the definition 
of the bleeding phenotype and clinical management 
of these patients, (iii) the usefulness and feasibility 
of prophylaxis with bypassing agents in the treatment 
of patients with inhibitors, (iv) the identification of 
predictive factors for inhibitor eradication, and (v) novel 
therapeutic approaches and molecules for the treatment 
and/or eradication of inhibitors. The aim of this review 
is to give an update on each of these issues with a focus 
on the current state-of-the-art knowledge and practice 
from the authors' personal perspective. This review 
focuses mainly on factor VIII inhibitors as these occur 
much more frequently in clinical practice.
Risk factors for inhibitor formation
The formation of inhibitors to the deficient clotting 
factor is the major complication of factor replacement 
therapy worldwide. Some of the risk factors for inhibitor 
formation, such as the underlying molecular defect 
affecting the F8/F9 gene, are well established7 while 
the importance of other factors such as the type of 
clotting factor concentrate remains hotly debated and 
poorly understood8-11. Increasing our understanding of 
these factors is critically important if we are to achieve 
our goal of predicting and ultimately reducing this 
complication of haemophilia treatment (Table I).
The marked difference in the rate of inhibitor 
formation between haemophilia A and B patients with 
the sam e laboratory phenotype can be attributed to 
two main factors: the causative genetic abnormality 
and differences in recognition by the immune system. 
Haemophilia A is unusual among monogenetic disorders 
in having a very high proportion of gross genetic 
abnormalities. These include large insertions and/or 
deletions and complex rearrangements which together 
account for about 50% of severe cases compared with 
7-8% in haemophilia B12,13. This overrepresentation of 
gross abnormalities is due to two well-characterised 
inversions caused by recombination events between 
homologous sequences within intron 22 or intron 1 and 
All rights reserved - For personal use only 
No other uses without permission
© 
SIM
TI
 Se
rvi
zi 
Srl
s320
Gomez K et al
Blood Transfus 2014; 12 Suppl 1: s319-29 DOI 10.2450/2013.0246-12
their extragenic counterparts14. Gross abnormalities 
inevitably result in a null allele with little prospect 
of translation into peptides capable of tolerising the 
immune system. In comparison, alleles with missense 
and some nonsense mutations, which cause the vast 
majority of cases of severe haemophilia B15, can 
sometimes be translated into peptides. Although these 
have no clotting factor activity and may not even be 
detectable as circulating antigen, they may be sufficient 
to tolerise the immune system to some parts of the wild-
type clotting factor. The incidence of inhibitor formation 
is, therefore, significantly less with severe disease 
caused by single nucleotide abnormalities.
The molecular risk factors are not limited to the 
disease-causing mutation. The higher rate of inhibitor 
formation in Afro-Caribbeans than in Caucasians is 
probably due to other genetic factors16. For such a large 
gene, there are relatively few polymorphisms in F817. 
Measurement of the frequencies of F8 haplotypes showed 
clear differences between racial groups. In Caucasians a 
single haplotype predominates in 93% of the population. 
In contrast, three haplotypes of similar frequency 
(22-35%) are found in Afro-Caribbeans16. As the two 
currently available full-length recombinant protein 
products correspond to two of these haplotypes there is 
potential for a mismatch with the recipient's haplotype. 
This is potentially more of an issue for Afro-Caribbean 
patients because of their variable haplotype. However, 
the higher prevalence of inhibitors among haemophilia 
A patients of African descent in Brazil was not related 
to the presence of these F8 haplotypes18. It may be that 
other genetic risk factors are implicated in the higher 
susceptibility to inhibitor development in haemophilia 
A patients of African origin. 
Genetic variation in critical immune regulatory 
genes may also play a role. It has been suggested that 
polymorphisms in a variety of these genes, including 
those coding for interleukin-10 (IL10), tumour necrosis 
factor-alpha (TNFα) and cytotoxic T-lymphocyte antigen 4 
(CTLA4) may be important19. HLA class II type, with clear 
differences in the incidence of specific haplotypes between 
races, is also a major determinant, as discussed below.
Although much of the initial research into 
inhibitor formation focused on cases with gross gene 
abnormalities, there is relatively little information about 
the immunogenicity of different mutations that we can 
learn from these defects because they are not associated 
with any protein production. Of potentially greater interest 
are the few missense mutations, some of which do not 
necessarily result in severe disease, that are associated 
with a higher rate of inhibitor formation than normal. 
Compared with an overall inhibitor incidence of 8%20 for 
all missense mutations, Arg2150His (20%), Arg2209Gln 
(16%) and Trp2229Cys (29%) are associated with an 
unexpectedly high rate of inhibitor formation, although 
their phenotype is generally mild or moderate7,20. This 
suggests that there are critical differences in the epitopes 
presented by the mutated protein when compared with 
wild-type factor VIII (FVIII). The interaction between 
Arg2150His and the major histocompatibility complex 
has been investigated in one study. The findings suggested 
that this mutation, in combination with specific HLA 
class II types, could be associated with the formation of 
T-cell clones with specificity for wild-type FVIII21. Even 
with these mutations, inhibitors occur in a minority of 
patients indicating that epitopic differences interact with 
other mechanisms in stimulating the immune response. 
Unravelling these interactions is the focus of ongoing 
research.
The difference in the rate of inhibitor formation 
between patients with haemophilia A or B is not simply 
due to genetic factors. Factor IX (FIX) is one of several 
serine proteases with high conservation of tertiary 
protein structure. Processing of peptides derived from 
other members of the protein superfamily may help to 
tolerise the immune system to FIX even when there is 
a null F9 allele. FVIII has no comparable full-length 
protein relatives, with only factor V (FV) sharing some 
similarity but with just 40% sequence homology22. 
In the circulation FVIII is closely associated with 
von Willebrand factor (vWF) which has a chaperone 
function. There is some evidence that the association 
with vWF reduces the immunogenicity of FVIII23. If this 
protective effect is significant, one would expect that 
replacement therapy with FVIII complexed with vWF 
might be less likely to induce inhibitor formation than 
pure FVIII protein. On the basis of these considerations, 
the most contentious issue concerning risk factors 
for inhibitor development in previously untreated 
patients with severe haemophilia A is the role of the 
FVIII concentrate type with conflicting data deriving 
from several studies comparing the rates of inhibitor 
Table I - Risk factors for inhibitor formation.
Clear evidence of increased risk of inhibitor formation
F8 mutation type Gross genetic abnormalities
Mutations resulting in a null allele
Specific missense mutations: 
R2150H, R2209Q, W2229C
Ethnicity Afro-Caribbean
Young age at first treatment Treatment before 6 months age
Treatment during co-existent 
inflammation
Weaker or uncertain evidence of risk
HLA type
F8 polymorphisms
Factor concentrate type Recombinant products may 
represent a higher risk
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Current practice in inhibitor management
formation with recombinant or plasma-derived products. 
The largest meta-analysis indicated that the pooled 
inhibitor incidence rate was significantly higher with 
recombinant products (27%) than with plasma-derived 
products (14%)9, although this difference was attributed 
to the variability in inhibitor monitoring over the last 
decades. This question remains unresolved and is the 
focus of the "Survey of Inhibitors in Plasma-Product 
Exposed Toddlers", the SIPPET project: an international, 
randomised controlled trial of plasma-derived and 
recombinant concentrates in previously untreated 
patients with severe haemophilia with development 
of inhibitors as the primary measured outcome 
(http://www.clinicaltrials.gov, NCT01064284).
There are several environmental risk factors that 
influence the risk of inhibitor formation such as intensive 
treatment in the presence of inflammation and treatment 
during infancy12. It is also well recognised that most 
inhibitors develop during the first 50 days of exposure7. 
The use of alternative therapies such as desmopressin 
or bypassing agents might lower the risk24. The use 
of immunosuppression in an attempt to reduce the 
inflammatory response to acute haemorrhage has been 
tried but appears to have little overall benefit25. Thus 
current strategies focus on avoiding other immune 
stimuli such as elective surgery or immunisation during, 
or in close proximity to, early treatment exposure26.
The recently published multicentre RODIN study 
which prospectively followed up paediatric patients 
up to 75 exposure days over an 11-year period 
evaluated treatment-related risk factors for inhibitor 
development27. In this study, recombinant and plasma-
derived factor VIII products conferred similar risks 
of inhibitor development, and neither the content of 
vWF in the products nor switching among products 
was associated with the risk of inhibitor development. 
Second-generation full-length recombinant products 
were associated with a higher risk than that associated 
with third-generation products27.
Treatment strategies based on the risk of inhibitor 
formation
With our knowledge about risks associated with 
inhibitor formation in haemophilia patients, the 
possibility of modifying treatment strategies, especially 
for patients thought to be at higher risk of inhibitor 
formation, could be an option. From the published 
literature it is clear that the strongest independent risk 
factors for inhibitor development in previously untreated 
patients with severe haemophilia A are a family history of 
inhibitors, null F8 mutations and intensive treatment8. In 
this light, any condition that favours intensive treatment 
should be avoided if possible: elective surgery including 
insertion of central venous access devices should be 
postponed and the occurrence of major bleeds should be 
minimised by starting prophylaxis as soon as possible. 
The possible protective role of early prophylaxis with 
a once-weekly regimen and any influence of product 
type on inhibitor development need to be proven before 
further conclusions can be drawn. Currently there are 
conflicting data on whether product type influences 
the risk of inhibitor development9,28. Italian national 
guidelines indicate recombinant products as the first 
choice in previously untreated patients with haemophilia, 
irrespectively of the severity of their disease29.  In Brazil, 
until 2012, all haemophilia A patients were exclusively 
treated with plasma-derived FVIII30. The prevalence of 
inhibitors in all haemophilia A patients is about 9-11%, 
and the incidence is still to be determined30. However, 
it is not currently possible to affirm that the occurrence 
of inhibitors among Brazilians, often of African descent, 
who have not been exposed to recombinant FVIII, is 
lower than that in other populations18. Likewise, our 
current knowledge does not enable us to suggest one 
product in preference to another in situations during 
which patients are subject to an increased inflammatory 
response, such as surgery. 
It is clear that the use of early prophylaxis in 
patients with severe haemophilia reduces the risk of 
joint damage31. However, it may also increase the risk 
of inhibitor formation32, raising the question of whether 
patients whose disease is caused by a gross genetic 
abnormality or who come from high-risk ethnic groups 
should start prophylaxis later or use some modified 
regimen. At present we do not understand enough to 
be able to answer this question completely. Based on 
our current knowledge, a risk-benefit analysis, taking 
into account both musculoskeletal complications and 
inhibitor development, should guide practice and policy. 
Musculoskeletal complications last life-long, and they 
are still costly to manage with suboptimal outcomes33, 
whereas inhibitor development affects only a subset of 
high-risk individuals13. Moreover, the main advantage 
of prophylaxis is to avoid the risk of intensive treatment. 
These considerations argue in favour of early prophylaxis 
in high-risk patients, preferably with a full regimen (3×/
week or every other day), to prevent arthropathy and 
support the management of inhibitors if they develop. 
A different approach to managing high-risk patients is 
to initiate treatment with low-dose prophylaxis once 
weekly at an early stage before the first bleed. The main 
goal of this strategy is to avoid peaks in the treatment 
within this "tolerisation phase" until 50 days of exposure 
have been achieved and thereby prevent inhibitor 
development. This regimen could possibly be adapted to 
reflect the risk of inhibitor development. A prospective study 
assessing a once-weekly prophylactic regimen together with 
the minimisation of immunological danger signals was 
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initiated early in 2012 (the Early Prophylaxis Immunologic 
Challenge [EPIC] Study, NCT01376700), however due to 
the unexpectedly high incidence of inhibitor development 
the study has recently been put on hold. 
Characterisation of the bleeding phenotype of 
patients with inhibitors
The question of whether the bleeding phenotype 
of patients with inhibitors differs from that of patients 
without inhibitors remains unanswered. It could be 
assumed that in the presence of inhibitory antibodies 
the bleeding tendency might be more severe; however, 
to our knowledge this correlation has never been clearly 
described in the published literature nor investigated 
directly. Moreover it is difficult to address this issue 
retrospectively since the outcomes usually applied 
to define the bleeding phenotype in this subgroup of 
patients are bleeding frequency and treatment of each 
bleeding episode. Indeed such features may vary greatly 
even in the same patient given that the clinical response 
to bypassing agents is difficult to predict and that these 
agents do not give the overall success rates obtained 
with factor replacement therapy in patients without 
inhibitors34. In the COCIS study, aimed at evaluating 
the cost of care related to the presence of long-standing 
high-titre inhibitors in patients with haemophilia, the 
average bleeding frequency reported was 0.6 events per 
patient per month35, which does not differ dramatically 
from that observed in a series of adult patients with 
severe haemophilia treated on demand36. However 
this result could have been influenced by the fact that 
patients with an inhibitor tend to be less physically 
active because of the lack of preventative treatment 
strategies35,37. What is clear from published data is that 
the orthopaedic status of patients with inhibitors is 
indeed worse than that of inhibitor-free patients37; such 
observations should, however, be interpreted cautiously 
since they could be the result of the reluctance to perform 
orthopaedic surgery in this subgroup of patients due to 
the high bleeding risk and related direct and indirect 
costs rather than of the bleeding phenotype per se. In a 
surveillance report of the Centers for Disease Control 
and Prevention in the United States which included 
more than 8000 patients with haemophilia, risk factors 
for limitation of the range-of-motion of joints were 
evaluated in 4343 eligible patients38. The evaluation 
showed that irrespective of disease severity, limitation 
of the range-of-motion of joints increased with age 
and body mass index, and that in patients with severe 
disease the presence of inhibitors was an independent 
risk factor for range-of-motion limitation even at a young 
age38. Unfortunately, in this report data on bleeding 
frequency were only correlated with disease severity 
but not with the presence of inhibitors. The evaluation 
of the orthopaedic status as a surrogate marker of 
bleeding frequency and severity was the major aim of 
the European Study on Orthopaedic Status (ESOS), 
a multicentre, non-interventional, cross-sectional, 
case-control study in which three cohorts of patients 
were evaluated: two cohorts of patients with severe 
haemophilia A or B and inhibitors aged 14-35 or 36-65 
years and one cohort of patients aged 14-35 years with 
severe haemophilia A or B but without any history of 
inhibitors37. Patients with inhibitors were hospitalised 
for orthopaedic procedures more frequently than those 
without inhibitors, irrespectively of age. Disability, the 
need for walking aids and joint pain were more frequent 
among the former patients. Similarly, clinical and 
radiological orthopaedic scores were worse in patients 
with inhibitors than in an age-matched group of patients 
without inhibitors37. In this study there was no difference 
in the annual bleeding frequency with respect to muscle 
bleeds across the three cohorts; however, the frequency 
of joint bleeds in young patients with inhibitors was 
similar to that in their age-matched controls but double 
that in the elderly, suggesting that end-stage joint 
damage rather than the presence of inhibitors per se 
may influence the bleeding phenotype in the long term37.
No prospective study comparing patients with and 
without inhibitors with respect to bleeding phenotype 
has been performed and published so far. The definition 
of the bleeding phenotype in inhibitor patients is an 
important clinical issue since it may have a strong impact 
on treatment strategies, especially in children.  
Treatment strategies based on the bleeding phenotype
Tailoring treatment of haemophilia patients with 
inhibitors based on predicted bleeding tendency and 
phenotype would be a very interesting approach. 
Indeed prediction of the bleeding tendency in the 
presence of inhibitors may guide clinicians in 
tailoring treatment by starting immune tolerance 
induction (ITI) as soon as possible, perhaps using 
prophylaxis with bypassing agents in order to avoid 
joint bleeds until having eliminated the inhibitors. In 
this light the use of bypassing therapy for bleeding 
episodes needs to be further optimised. However, 
up to now we are still some way from being able to 
reliably predict bleeding tendencies which would be 
a prerequisite to tailoring treatment for individual 
patients. And even if better predictive algorithms 
did exist, the approach of early initiation of ITI 
coupled with prophylaxis with bypassing agents is 
very expensive. In the light of this it is important 
to bear in mind that high-dose ITI can reduce the 
bleeding tendency even in patients with high-titre 
inhibitors and very low FVIII levels39. ITI could, 
therefore, be initiated without bypassing agents and 
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prophylaxis with recombinant activated factor VII 
(rFVIIa) or plasma-derived activated prothrombin 
complex concentrate (aPCC) introduced only when 
patients bleed regularly during ITI treatment.
Management of patients with inhibitors: 
prophylaxis
The management of haemophilia in patients with 
inhibitors, including prophylactic treatment, poses 
several difficulties: in the presence of low-titre, low-
responding inhibitors (historical inhibitor peak never 
exceeding 5 BU/mL) FVIII/FIX concentrates can be 
used although at higher doses and/or shorter intervals 
in order to saturate inhibitors and promote haemostasis. 
In contrast, if high-titre, high-responding inhibitors 
(historical inhibitor peak that exceeded 5 BU/mL at 
least once) are present, FVIII/FIX concentrates cannot 
be given in large enough quantities to overcome the 
neutralising activity of the inhibitors and haemostasis 
should be ensured by using alternative drugs, referred 
to as bypassing agents34. Up to date, bypassing agents 
used in this setting are plasma-derived aPCC (FEIBA®, 
Baxter, Vienna, Austria), and rFVIIa (NovoSeven®, 
Novo Nordisk, Bagsvaerd, Denmark)40. Their efficacy in 
controlling bleeding episodes has been widely proven in 
patients with haemophilia and inhibitors41-44. However, 
it is often unpredictable even in the same patients, 
and usually lower when compared to prophylaxis 
using factor replacement in non-inhibitor patients. 
Moreover, the use of these bypassing agents according 
to prophylactic regimens still needs to be defined, not 
only in terms of efficacy, but also considering costs and 
the potential risk of thromboembolic events. 
Recently, several case series using bypassing agents 
(both aPCC and rFVIIa) for prophylaxis therapy have 
been reported, and three meta-analyses summarise most 
of these cases45-47. These reports are mostly retrospective 
and there is no consensus of regimens used, bleeding 
phenotype and/or previous treatment history. Table II 
summarises the information from the case series, meta-
analyses and randomised studies using bypassing agents 
for prophylaxis. 
The first controlled, randomised study on secondary 
prophylaxis for inhibitor patients compared the 
effectiveness of two different rFVIIa doses, 90 μg/kg 
or 270 μg/kg per day, over a 3-month period to reduce 
Table II - Summary of previous reports of prophylaxis treatment using bypassing agents for haemophilia patients with inhibitors.
Reference Patients' data Bypassing agent therapy Haemostatic outcome
aPCC prophylaxis studies
DiMichele & Negrier, 200648
(Post-licensure surveillance 
study)
14 sHA 
Mean age 25 y 
(range 3-61)
Mean dose 69 IU/kg
(range 15-100)×1/d  
or ×1/wk or alternate days
Mean period 19.5 mo (range 0.25-26)
53% mean reduction in bleed frequency 
(range 10-85)
No thrombotic event, no AE
Valentino, 201049
(Meta-analysis of 6 studies)
34 sHA
Mean age 10.1 y 
(range 3-39)
Mean dose 78.5 U/kg
(range 50-100)×1/d or ×1/wk
Mean period 2.3 y
(range 0.1-6)
57% reduction in bleed frequency
76% reduction in joint bleeding
No thrombotic event
Leissinger et al., 20116
(Randomised cross-over study)
26 sHA
Median age 28.7 y
(range 2.8 - 67.9)
6 mo prophylaxis with 85 U/kg ±15% 
3×/week 
vs
6 mo on-demand with 85 U/kg ±15%
62% reduction in all bleeds
61% reduction in joint bleeds
No thrombotic events,
1 severe allergic reaction
rFVIIa prophylaxis studies
Brackmann et al., 200050 2 sHA, 2 sHB
Age range 0.5-26 y
90 g/kg bid to 2-3×/week
Period 2-27 mo
Slight decrease in bleeding episodes during 
prophylaxis with rFVIIa compared to aPCC
Young et al., 200551 1 sHA, 1 sHB
Age 3-15 y
200 g/kg for 6-12 h
Period 12-25 mo
Decrease in bleeding episodes and hospitalisation
Morfini et al., 200752 12 sHA, 1 sHB
Age range 2-30 y
220 g/kg/d to  200-250 g/kg/wk
Period 4-48 mo
Decreased bleeding episodes in 12 out of 13 
patients
Konkle et al., 20075
(Randomised cross-over dose 
study)
21 sHA, 1 sHB
Mean age 15.7 y 
(range 5-56)
3 mo 90 g/kg/d 
vs
3 mo 270 g/kg/d 
45% reduction in bleed frequency with 90 g/kg/d
59% reduction in bleed frequency with 90 g/kg/d
Jimenez-Yuste et al., 200953 5 sHA 90-100 g/kg/d
Median period 9 mo
(range 6-22)
Reduction of median bleeding rates from 4 
prior prophylaxis to 1 in the same period with 
prophylaxis
Young et al., 201254
(Retrospective, observational 
study)
71 sHA, 15 sHB 
Mean age 6 y
(range 0.1-52)
Median dose and frequency:
Children (N =61) 139 g/kg 7×/wk
Adolescents (N =7) 165.3g/kg 5.5×/wk
Adults (N =18) 133.3 g/kg 3/wk
46% reduction in bleed frequency for all patients; 
52% reduction in bleed frequency for patients 
with ≥1 bleed/mo prior prophylaxis
sHA: severe haemophilia A; sHB: severe haemophilia B; y: years; d: days; wk: weeks; mo: months; AE: adverse event.
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bleeding frequency5. After a 3-month pre-prophylaxis 
observation period, only patients with high rates of 
bleeding episodes were considered for treatment in this 
study. Another 3-month post-prophylaxis observation 
period was also considered for the assessment. Although 
no statistically significant difference in rates of bleeding 
episodes between patients give the two doses, a 
significant difference was found between the 3-month 
pre-prophylaxis period and the prophylaxis period. The 
study also demonstrated that the prophylactic effect 
of rFVIIa persisted over a 3-month post-prophylaxis 
period, and that the patients had an improvement in 
health-related quality of life. Similar results were seen 
with a longer period of prophylactic treatment using 
rFVIIa in the observational PRO-PACT study, evaluating 
the frequency and pattern of bleeding episodes in 
haemophilia patients receiving preventative treatment54.
Recently, equivalent beneficial effects were 
demonstrated with aPCC in the PRO-FEIBA study6. 
This was a prospective, randomised, crossover study, 
comparing a 6-month period of aPCC prophylaxis with 
6 months of on-demand therapy. The use of aPCC dosed 
at 85 U/kg ± 15% given on 3 non-consecutive days 
per week was associated with a 62% reduction in all 
bleeds and a 61% reduction in joint bleeds as compared 
with on-demand therapy. It is interesting to observe 
that for a group of patients with a good response, the 
overall reduction in bleeding rate was 84%. However, 
for another group of patients with frequent bleeding 
episodes the reduction during the prophylactic period 
was less, and in fact two of ten patients in this group had 
more bleeding events during prophylaxis and one patient 
died of a cranial haemorrhage. None of the patients 
enrolled in these three prospective studies using rFVIIa 
or aPCC showed any sign of thromboembolic events.
Generally, although studies have shown an overall 
reduction in joint bleeding episodes during the period 
of prophylaxis with bypassing agents5,49,52,53, the benefit 
of bypassing agents in preventing or reducing joint 
deterioration in the long term is not evident. In a recent 
publication from the Hemophilia Treatment Centers 
Network in the United States, secondary prophylaxis 
significantly decreased the number of haemarthroses 
in patients with inhibitors when compared to episodic 
treatment in this group of patients55. However, 
prophylaxis was not shown to be associated with a 
significant improvement in the target joint range of 
motion or to prevent new target joint development. 
Prophylactic treatment strategies in patients with 
inhibitors
Although the abovementioned studies suggest that 
prophylaxis with bypassing agents could be effective 
in patients with inhibitors, they also emphasise the 
large inter-individual difference in dose-response to 
bypassing agents and the potential role for variables 
other than haemostatic agents in influencing the final 
outcome of a therapeutic approach (e.g. bleeding 
phenotype, presence of target joints and/or established 
joint damage, undefined mechanism of action). 
This contributes to the difficulty in establishing a 
consensus on prophylactic treatment using these 
agents. One approach to be considered could be to 
initiate prophylactic treatment in inhibitor patients in 
whom ITI treatment has been unsuccessful. However, 
prophylaxis using bypassing agents for inhibitor 
patients is very costly and not available for all patients 
in all countries. In this case, short-term prophylaxis 
with defined short-term goals may be possible as an 
alternative. If prophylactic treatment is applied prior 
to the initiation of ITI treatment or the patient is under 
consideration for ITI, rFVIIa would be the preferred 
choice while awaiting a decline in inhibitor titres to 
avoid an anamnestic response as this may occur with 
aPCC in some patients53,56,57. 
The role of primary prophylaxis with bypassing 
agents in children with newly developed inhibitors 
is being investigated in the frame of a randomised 
controlled clinical trial, the ENJOIH study (http://
www.clinicaltrials.gov, NCT01105546), evaluating 
whether daily prophylaxis with 90 μg/kg rFVIIa 
is superior to on-demand treatment in preventing 
joint bleeds and consequently joint damage in these 
children.
Management of patients with inhibitors: 
immune tolerance induction
Despite the recent achievements in treatment and 
prevention of bleeding events with bypassing agents the 
primary goal when managing inhibitor patients remains 
eradication of the inhibitor by ITI treatment. Successful 
ITI is able to normalise FVIII pharmacokinetics and 
improve the patient's quality of life.
The outcome of ITI is influenced by both patient- 
and treatment-related factors. ITI is successful in up 
to 80% of patients with haemophilia A and 30% of 
patients with haemophilia B58. There are different 
dosing regimens to achieve immune tolerance. The 
Bonn protocol recommends high-dose FVIII of 100-
150 IU/kg body weight twice a day59,60, the Dutch van 
Creveld protocol 25-50 IU FVIII/kg body weight three 
times a week61. The  German Guidelines (Deutsche 
Ärztekammer 2008) recommend 50-100 IU/kg body 
weight FVIII three times a week for ITI in children 
with low responding inhibitors (<5 BU/mL) and 100-
200 IU/kg body weight FVIII twice a day for children 
with high responding inhibitors (>5 BU/mL) with 
76% of success62. The German ITI-registry (GITR) 
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reported full success in 78.6% of the 126 patients 
treated over the period from 1993 to 199958. Data 
from the National Italian Registry on ITI (PROFIT 
study63) show that the regimen used for ITI in Italy 
is a median dose of 100 IU/kg body weight per day 
and that in 74% of cases rFVIII is used for primary 
ITI since in the vast majority of patients the product 
employed at the time of inhibitor development is 
further applied. In South Africa, there are currently 
no published guidelines regarding ITI treatment, and 
the Dutch protocol is usually followed. Similarly, 
no single protocol predominates in the UK, leading 
to considerable variation in which ITI regimens are 
used including high-dose regimens similar to the ones 
mentioned above based on the Malmö protocol64 or 
intermediate doses based on the Dutch protocol. 
It is difficult to compare different studies and 
registries because the patients' characteristics and 
definition of success of ITI-outcome vary widely. 
In the registries mentioned above, the outcome of 
ITI was poorer in patients with high historical peak 
titres. The first study with a selection of patients with 
comparable risks and a clear definition of outcome was 
the International Immune Tolerance Study (I-ITI)39. 
This study compared a high-dose regimen (200 IU/kg 
body weight per day) versus a low-dose regimen (50 
IU/kg body weight three times a week) in "good risk 
patients" (patients with historical inhibitor titres <200 
BU/mL and immediate pre-ITI titres <10 BU/mL). It 
was prematurely terminated because of a significantly 
increased number of bleeds in the low-dose arm during 
ITI and post-ITI prophylaxis. ITI success rates were not 
different in the two arms; however, ITI was more slowly 
achieved in the low-dose arm39. 
A retrospective analysis of the Frankfurt experience, 
which indicated that ITI treatment with high-purity 
FVIII resulted in a lower treatment success rate (29%) 
as compared to historically obtained results using 
vWF-containing agents (91%), raised the question 
of whether the type of FVIII product may predict 
ITI outcome65. However, due to variable use of these 
agents in the different registries, this observation could 
not be confirmed by either the International Immune 
Tolerance Registry (IITR) or the North American 
Immune Tolerance Registry (NAITR)66-68. Both 
recombinant and plasma-derived FVIII can lead to 
successful ITI outcomes in good and poor risk patients 
as a recent review by Franchini et al. indicates69. Two 
retrospective analyses of poor-risk cohorts in the USA 
and one prospectively followed series of Italian and 
Spanish poor-risk patients have, however, shown that 
the epitope specificity of the anti-factor VIII antibody 
may influence whether ITI with vWF-containing FVIII 
agents is successful70-72.
In Germany, ITI treatment is started very early for 
all patients, even those with high inhibitor titres, and 
pursued for a relatively long time58,59. Data from the 
National Italian Registry on ITI between 1996 and 
200763 show that the median age at initiation of ITI 
was 5.6 years and that the median pre-ITI inhibitor titre 
was 4 BU/mL, indicating that ITI is usually performed 
in childhood and once the inhibitor titre has dropped 
to below 10 BU/mL. ITI treatment in Germany and 
Italy is usually initiated with the factor product 
previously used by the patient; a switch of factors is 
avoided if possible. In some German centres, if ITI is 
not successful after 6 months, the patient is switched 
to a vWF-containing regimen65. In the absence of 
long-term success (after 12-24 months), in Europe, 
immunosuppressive agents are often considered, e.g. 
rituximab73. Rituximab is a monoclonal antibody 
against CD20, a protein found only on B cells, and 
depletes B cells in the circulation and lymphoid 
tissues74.  Successful use of rituximab for ITI has been 
reported in case studies and small series. A review of 
available data lists 29 reports comprising 49 patients 
with congenital haemophilia A or B: 23 patients 
with severe haemophilia A, 16 patients with mild/
moderate haemophilia A and five patients with severe 
haemophilia B75. Fifty-seven percent of these patients 
had previously received ITI. Eradication of inhibitors 
was achieved in 67% of patients with a durable result 
in 53% of patients. Concomitant FVIII administration 
was significant for a positive outcome, whereas severe 
disease had a negative impact75.
Immune tolerance induction treatment strategies
Taking the current evidence into account ITI should 
be performed with high doses (200 IU/kg body weight 
per day) in patients with high-titre inhibitors with the 
product used before the development of the inhibitor. 
Consensus recommendations of an international 
workshop on ITI suggested high-dose regimens of 
≥200 IU/kg body weight per day for poor-risk patients 
(patients with historical inhibitor titres >200 BU/mL 
and/or immediate pre-ITI titres >10 BU/mL and/or time 
since inhibitor diagnosis exceeding 5 years), whereas 
no recommendation for any particular ITI regimen was 
made for good-risk patients57. If there is no significant 
reduction in the inhibitor titre after 6 to 9 months, the 
patient could be switched from recombinant or high 
purity to vWF-containing FVIII concentrates. If the 
inhibitor titre is not reduced after 12 months, two 
options should be discussed: long-term prophylaxis 
with aPCC or rFVIIa (less effective than FVIII 
treatment) or combining ITI with immunosuppressive 
agents such as rituximab or on-demand treatment with 
bypassing agents.
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New treatment options for patients with 
inhibitors
Despite their well-documented efficacy and safety 
profiles, aPCC and rFVIIa have pharmacokinetic and 
therapeutic shortcomings which could be improved. Both 
are known to be thrombogenic even at recommended 
therapeutic doses. In ex-vivo studies, both agents were 
unable to generate thrombin to the same level as seen 
in patients without inhibitors when treated with FVIII 
or FIX76. However, it is unclear how much improvement 
in thrombin generation is required to achieve clinical 
benefit and in some patients even a small improvement 
may be sufficient. Consequently, therapy with both 
bypassing agents is often associated with significant 
intra- and inter-individual variation in efficacy77. 
Both agents are widely used in the management of 
acute bleeding episodes with limited experience in 
prophylaxis.
A number of bioengineered bypassing agents are 
under development to improve on the shortcomings 
of currently available inhibitor therapies. The aims of 
the various development programmes are to produce 
rFVIIa drugs that are less thrombogenic, have a longer 
half-life, an increased ability to bind to platelets and 
increased potency with dual use in prophylaxis and the 
treatment of bleeds. Although a single novel rFVIIa 
encompassing all these features in one drug would be 
desirable, the strategic approach of product developers 
to date has been to focus on one or two of these FVII 
improvement features. Development approaches so far 
have been varied and include changes in amino acid 
composition, N-glycan mutations, pegylation, glyco-
pegylation and albumin fusion recombinant strategies. 
Table III is a summary of some of the haemostatic and 
pharmacokinetic features of these new agents most 
of which are already in advanced stages of clinical 
development.
In preclinical studies, vatreptacog alfa showed a 
more rapid onset of action and formed a stronger clot 
which was more resistant to fibrinolysis when compared 
to rFVIIa78-81. Although a phase II trial evaluating the 
safety and preliminary efficacy of vatreptacog alfa 
showed that it was well tolerated with no signs of 
thrombogenicity or immunogenicity and a high efficacy 
rate77, the development of this drug was discontinued 
following analysis of results of a phase III trial (http://
www.clinicaltrials.gov, NCT01392547) after a few 
patients had developed antibodies to vatreptacog alfa 
which were able to cross-react with rFVIIa.
A phase I, randomised, placebo-controlled clinical 
study was conducted in 16 non-bleeding subjects to 
investigate safety, tolerability and pharmacokinetic 
properties of BAY 86-615082. Pharmacokinetic 
analysis determined an increased half-life to a mean 
of 7 hours. Initial results indicated that BAY 86-6150 
was well tolerated and safe in the applied doses of up 
to 90 μg/kg. However, recruitment to a phase II study 
to evaluate the safety and efficacy of this molecule 
in the target haemophilia population was recently 
discontinued due to safety concerns (http://www.
clinicaltrials.gov, NCT01625390). 
A well established half-life extension strategy of 
pegylation was coupled to N-glycan modification 
by Novo Nordisk to produce glycopegylated rFVIIa 
(N7-GP). The  mechanism of prolongation of rFVIIa 
half-life appears to be multi-factorial with reduced 
renal clearance due to increased volume and reduced 
receptor-mediated clearance due to steric hindrance 
recently shown to be operative in vitro83,84. 
A novel approach to inhibitor treatment not related 
to rFVIIa is the use of recombinant B-domain deleted 
porcine FVIII (OBI-1). OBI-1 is a highly purified 
bioengineered form of porcine recombinant FVIII 
developed by Ipsen and Inspiration Biopharmaceuticals 
with the pro-coagulant and biochemical properties of 
porcine plasma-derived FVIII. In a preclinical mouse 
model of haemophilia A, OBI-1 showed significantly 
less immunogenicity than plasma-derived-FVIII. 
Furthermore, no inhibitors were detected in cynomolgous 
monkeys, treated with OBI-185. Results of the preclinical 
Table III - New bypassing agents for the treatment of haemophilia with inhibitors.
Current status Bypassing agent 
(developer)
Structural properties Haemostatic and 
pharmacokinetic properties
Current stage of clinical 
development
Discontinued studies vatreptacog alfa
(Novo Nordisk)
3 amino acid substitutions in 
rFVIIa molecule
High thrombin burst and rapid 
onset of action
Clinical development 
discontinued in phase III
BAY-86-6150
(Bayer Healthcare)
rFVIIa with 4 amino acid 
changes and two N-glycan 
mutations
Increased binding to platelets 
and 2-3 fold increase in  half-
life
Clinical development 
discontinued in phase II/III
N7-GP
(Novo Nordisk)
40k glycoPEGlated rFVIIa 3- to 4-fold increase in half-life Clinical development 
discontinued in phase II
Continuing studies OBI-1
(Inspiration)
B-domain deleted 
recombinant porcine FVIII
Haemostatic activity in 
inhibitor patients
Phase III
CSL 689
(CSL Behring)
Albumin fusion to rFVIIa 
via glycine-serine linker
6- to 9-fold increase in half-life 
in preclinical studies
Phase II
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and clinical studies suggest that OBI-1 may be less 
immunogenic and safer than Hyate:C in inhibitor 
patients86,87. In an open-label clinical phase II trial 
conducted in patients with haemophilia A and inhibitors 
against human FVIII, who were experiencing a non-life 
or -limb threatening bleed, OBI-1 was well tolerated and 
did not cause any drug-related serious adverse events85. 
The current clinical programme in the development of 
OBI-1 is to evaluate efficacy in surgical patients who 
have historically demonstrated a poor response to aPCC 
or rFVIIa (http://www.clinicaltrials.gov, NCT01434511).
Other novel therapies currently in the early phase 
of clinical development include anti-tissue factor 
pathway inhibitor (anti-TFPI) therapy. The potential 
benefits of this treatment are its non-intravenous route 
of administration and longer duration of action which 
will make prophylaxis in inhibitor patients possible. No 
clinical data are currently available as no clinical trials 
with this new product have yet been completed.
Looking at the new molecules that are under 
development for the treatment of patients with inhibitors 
it is clear that the major unmet needs in this setting 
include the following:
- The short half-life of rFVIIa that renders therapy 
difficult or even unfeasible for patients with difficult 
venous access, in particular children. The short 
half-life also limits implementation of successful 
prophylactic programmes using these agents.
- The need for prolonged therapeutic courses in order 
to control bleeds in a fashion comparable with 
FVIII/FIX replacement therapy: for FVIII one to 
two infusions are enough to resolve an acute bleed 
in over 90% of cases if treated early, as data from 
several clinical trials with various recombinant 
FVIII concentrates have shown1,88,89. In contrast, in 
patients with inhibitors treated with rFVIIa at least 
three to four injections at very high doses are usually 
required to control approximately 90% of bleeds43,90, 
and treatment with aPCC every 12 hours leads to 
the resolution of only 76% of joint bleeds after 36 
hours43. Moreover, if treatment with bypassing agents 
is started late with respect to the occurrence of first 
symptoms a whole therapeutic course may last 5 to 
6 days, a delay that may enable the development of 
difficult-to-reverse tissue damage.
- The ease of laboratory monitoring: rFVIIa or 
aPCC can currently be monitored by global 
haemostatic assays such as thrombin generation 
or thromboelastography. These assays are not 
well standardised and their availability is limited 
compared to that of clotting factor assays. One of 
the potential advantages of porcine FVIII is that it 
can be monitored by clotting factor assays using an 
appropriate standard.
Concluding remarks
Inhibitor development is a complication of haemophilia 
treatment that generates many challenges. These include 
identification of which patients are at risk, prevention 
and treatment of bleeding episodes and identification of 
predictors of successful inhibitor eradication. Current state-
of-the-art knowledge and practice in these areas indicate 
that there has been significant progress with advances being 
made which will contribute to our better understanding 
of inhibitor risk stratification, pathophysiology and 
management. The rapid evolution of novel therapies 
should lead to increased therapeutic options with improved 
efficacy for haemophilia patients with inhibitors.
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